The non-linear relationship between muscle mass and BMI calls into question the use of BMI as a major criterion for eligibility for bariatric surgery

**ARTICLE INFO**

**Keywords**
- Bariatric surgery
- Body mass index
- Diabetes
- Muscle mass
- Obesity

Type 2 diabetes mellitus (T2DM) is a growing health problem worldwide, largely because of the high burden of increasing obesity rates [1–3]. In comparison with intensive medical therapy, Roux-en-Y gastric bypass (RYGB) surgery is a particularly effective intervention for T2DM, with about 60% of obese individuals achieving T2DM remission (DR) and sustained weight loss [4,5]. Several predictive factors for DR have been identified, including age, disease duration, glycemic control, and insulin usage [6,7]. However, the predictive performance of existing methods is modest, especially for patients in the lower BMI range (<30 kg/m^2) who show considerably poorer remission rates (range, 30%-40%) [8]. In addition, one-third of patients who underwent RYGB showed relapse within 5 years of initial remission [4]. Thus, novel DR-related factors are required in order to optimize preoperative evaluation and postoperative management. Indeed, the use of bariatric surgery worldwide is largely governed by a 1991 National Institutes of Health consensus statement that advocated BMI-based operative criteria [9], even though no direct evidence has been obtained to support the ability of BMI to predict DR after surgery [10,11]. One important but underexplored methodological limitation of this approach is that BMI does not discriminate between fat mass and fat-free mass (FFM). Skeletal muscle is the major component of FFM [12] and plays a critical role in whole-body glucose homeostasis [13].

A very recent study by Li et al. published in Diabetes Care [14] has revealed the potential relevance of muscle mass assessed by magnetic resonance imaging (MRI) or a predictive equation on BMI limitations in predicting DR after RYGB. It is concluded that a two-phase association exists between muscle mass and BMI and baseline muscle mass or estimated fat-free mass index (eFFMI) are associated with short- and long-term DR after RYGB. Previous studies had reported that individuals with higher BMIs have a larger skeletal muscle mass and fat mass, and the relationship between BMI and body component was thought to show a positive correlation [15]. In this study, the authors firstly provided compelling new evidence for the limitations of BMI in assessing body composition, with the muscle mass showing a significant threshold effect with increasing body weight (BMI cut-off = 31.88 for males and 32.66 for females). Similarly, at the inflection point (BMI = 33.71 for males and 33.91 for females), the increment in visceral fat changed despite not being statistically significant (P = 0.12) in males and being significant in females (P = 0.022). In contrast, subcutaneous fat did not show a breakpoint, which may be attributed to its larger capacity limit. These results indicated that a single BMI value cannot adequately reflect the dynamics of body composition, especially muscle mass. Next, in the longitudinal study for DR with a 5-year follow-up RYGB surgical cohort, psoas cross-sectional area and eFFMI were strong predictors for 1- and 5-year DR after RYGB surgery in Chinese T2DM patients, but BMI did not show such predictive ability. The presence of more muscle mass before surgery indicates a greater possibility of achieving complete DR after surgery.

In conclusion, the non-linear relationship between muscle mass and BMI may explain why BMI cannot adequately predict DR after surgery. The difference in DR rates between the high-BMI (>30 kg/m^2) and low-BMI populations reported in previous studies may be attributed to the differences in muscle mass between the two groups. This study (along with other published studies) call into question the rationale in using BMI as a criterion for eligibility for bariatric surgery. Predicted FFMI may be a simple parameter superior to BMI to be included in clinical guidelines for preoperative evaluation of bariatric surgery in the future. The fact that the study participants originated from a single ethnic group may in part limit the immediate generalizability of the results, at least until these are validated in other populations as well. Nevertheless, the findings are novel and offer valuable insight into potentially useful prognostic markers for successful diabetes remission in patients with obesity.

https://doi.org/10.1016/j.metop.2022.100164
Received 15 January 2022; Accepted 15 January 2022
Available online 19 January 2022
2589-9368/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
Funding information

None.

Declaration of competing interest

None.

References

[1] Vallianou NG, Geladari EV, Kounatidis D, Geladari CV, Stratigou T, Dourakis SP, Andreadis EA, Dalamaga M. Diabetes mellitus in the era of climate change. Diabetes Metab 2021;47(4):101205.
[2] Tsilingiris D, Vallianou NG, Dalamaga M. Prediabetes screening: questionable benefits in the golden years. Metabol Open 2021;10:100091.
[3] Koliaki C, Liatis S, Dalamaga M, Kokkinos A. Sarcopenic obesity: epidemiologic evidence, pathophysiology, and therapeutic perspectives. Curr Obes Rep 2019;8(4):458–71.
[4] McTigue KM, Wellman R, Nauman E, et al. Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass: the National Patient-Centered Clinical Research Network (PCORNet) bariatric study. JAMA Surg 2020:e200087.
[5] Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366(17):1567–76.
[6] Wang GF, Yan YX, Xu N, et al. Predictive factors of type 2 diabetes remission following bariatric surgery: a meta-analysis. Obes Surg 2015;25(2):199–208.
[7] Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care 2013;36(1):20–6.
[8] Baskota A, Li S, Dhakal N, Liu G, Tian H. Bariatric surgery for type 2 diabetes mellitus in patients with BMI < 30 kg/m2: a systematic review and meta-analysis. PLoS One 2015;10(7):e0122335.
[9] NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference panel. Ann Intern Med 1991;115(12):956–61.
[10] Cummings DE, Cohen RV. Bariatric/Metabolic surgery to treat type 2 diabetes in patients with a BMI < 35 kg/m2. Diabetes Care 2016;39(6):924–33.
[11] Cummings DE, Cohen RV. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2014;2(2):175–81.
[12] Davidson LE, Yu W, Goodpaster BH, et al. Fat-free mass and skeletal muscle mass five years after bariatric surgery. Obesity 2018;26(7):1130–6.
[13] Yokoyama I, Inoue Y, Moritani T, Ohtomo K, Nagai R. Simple quantification of skeletal muscle glucose utilization by static 18F-FDG PET. J Nucl Med: Off Publ, Soc Nucl Med 2003;44(10):1592–8.
[14] Li S, Yu H, Zhang P, et al. The nonlinear relationship between psoas cross-sectional area and BMI: a new observation and its insights into diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 2021;44(12):2783–6.
[15] Lee DH, Keum N, Hu FB, et al. Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study. Br Med J 2018;362:k2575.

Junli Liu* Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University Affiliated 6th People’s Hospital, Shanghai Diabetes Institute, Shanghai, China

Dimitrios Tsilingiris First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, 17 St Thomas Street, 11527, Athens, Greece

Maria Dalamaga Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece

E-mail address: madalamaga@med.uoa.gr.

* Corresponding author.

E-mail address: lijunli@sjtu.edu.cn (J. Liu).